See more : Rémy Cointreau SA (REMYY) Income Statement Analysis – Financial Results
Complete financial analysis of Zhejiang Shengda Bio-Pharm Co., Ltd. (603079.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zhejiang Shengda Bio-Pharm Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Gevo, Inc. (GEVO) Income Statement Analysis – Financial Results
- Challenger Limited (CGF.AX) Income Statement Analysis – Financial Results
- CTEEP – Companhia de Transmissão de Energia Elétrica Paulista S.A. (CTPTY) Income Statement Analysis – Financial Results
- Enli Technology Co.,Ltd (7728.TWO) Income Statement Analysis – Financial Results
- Shinden Hightex Corporation (3131.T) Income Statement Analysis – Financial Results
Zhejiang Shengda Bio-Pharm Co., Ltd. (603079.SS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.sd-pharm.com
About Zhejiang Shengda Bio-Pharm Co., Ltd.
Zhejiang Shengda Bio-Pharm Co., Ltd. engages in the research, development, production, and sale of food and feed additives worldwide. The company offers vitamins, such as biotin and folic acid, etc.; biological fresh-keeping agents, including nisin and natamycin; and intermediate APIs. It also produces natural food preservatives. The company is based in Tiantai, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 727.41M | 738.02M | 789.73M | 867.31M | 519.15M | 492.71M | 508.56M | 482.15M | 536.43M | 380.90M | 398.77M | 449.25M |
| Cost of Revenue | 653.22M | 607.17M | 561.27M | 393.74M | 326.62M | 327.41M | 316.25M | 310.54M | 262.50M | 244.06M | 263.06M | 221.26M |
| Gross Profit | 74.18M | 130.85M | 228.46M | 473.58M | 192.53M | 165.30M | 192.31M | 171.61M | 273.93M | 136.84M | 135.71M | 227.99M |
| Gross Profit Ratio | 10.20% | 17.73% | 28.93% | 54.60% | 37.09% | 33.55% | 37.82% | 35.59% | 51.07% | 35.93% | 34.03% | 50.75% |
| Research & Development | 42.92M | 37.42M | 39.64M | 35.69M | 27.90M | 21.39M | 22.88M | 23.91M | 26.62M | 21.04M | 18.03M | 23.15M |
| General & Administrative | 15.15M | 14.03M | 34.90M | 53.68M | 25.64M | 20.00M | 18.39M | 24.46M | 61.04M | 11.55M | 62.66M | 111.76M |
| Selling & Marketing | 5.89M | 13.25M | 12.47M | 28.58M | 18.50M | 17.12M | 15.33M | 19.75M | 21.36M | 14.92M | 13.38M | 24.91M |
| SG&A | 77.26M | 27.28M | 47.37M | 82.26M | 44.14M | 37.12M | 33.71M | 44.21M | 82.40M | 26.47M | 76.04M | 136.67M |
| Other Expenses | -324.68K | 43.95M | 65.25M | 74.27M | 49.54M | 1.08M | -831.30K | 10.63M | -422.54K | 266.32K | 21.49M | -4.39M |
| Operating Expenses | 119.21M | 108.64M | 152.26M | 192.22M | 121.58M | 106.91M | 88.75M | 114.95M | 153.75M | 79.00M | 79.44M | 140.23M |
| Cost & Expenses | 773.08M | 715.82M | 713.53M | 585.95M | 448.20M | 434.32M | 405.00M | 425.49M | 416.25M | 323.06M | 342.50M | 361.49M |
| Interest Income | 8.41M | 3.99M | 2.93M | 4.19M | 4.34M | 2.71M | 927.97K | 656.18K | 958.74K | 1.18M | 0.00 | 0.00 |
| Interest Expense | 1.83M | 4.56M | 5.76M | 4.64M | 11.07M | 6.22M | 5.02M | 4.07M | 5.61M | 5.90M | 11.11M | 10.56M |
| Depreciation & Amortization | 77.92M | 73.03M | 77.23M | 74.21M | 53.56M | 33.24M | 28.39M | 14.17M | 27.05M | 24.96M | 9.89M | 16.49M |
| EBITDA | 34.45M | 114.42M | 163.80M | 302.86M | 111.56M | 92.10M | 119.37M | 91.44M | 140.78M | 80.91M | 56.27M | 87.77M |
| EBITDA Ratio | 4.74% | 17.30% | 20.84% | 35.85% | 24.74% | 20.72% | 23.98% | 22.08% | 29.64% | 21.92% | 14.19% | 20.33% |
| Operating Income | -45.68M | 59.41M | 81.44M | 247.31M | 76.71M | 52.30M | 85.82M | 63.45M | 109.84M | 50.58M | 46.71M | 74.84M |
| Operating Income Ratio | -6.28% | 8.05% | 10.31% | 28.51% | 14.78% | 10.61% | 16.88% | 13.16% | 20.48% | 13.28% | 11.71% | 16.66% |
| Total Other Income/Expenses | 368.25K | -22.89M | -1.40M | -23.63M | -1.51M | 99.53K | 146.10K | 9.90M | -1.72M | -529.58K | 20.34M | -5.20M |
| Income Before Tax | -45.31M | 36.52M | 80.04M | 223.67M | 49.18M | 52.40M | 85.97M | 72.99M | 108.12M | 50.05M | 67.04M | 69.64M |
| Income Before Tax Ratio | -6.23% | 4.95% | 10.14% | 25.79% | 9.47% | 10.63% | 16.90% | 15.14% | 20.15% | 13.14% | 16.81% | 15.50% |
| Income Tax Expense | 8.89M | 6.08M | 8.22M | 33.70M | 11.42M | 9.81M | 13.36M | 12.05M | 21.41M | 6.26M | 9.95M | 16.23M |
| Net Income | -54.06M | 31.48M | 75.76M | 197.44M | 47.03M | 44.54M | 72.61M | 60.94M | 86.70M | 43.79M | 54.59M | 52.36M |
| Net Income Ratio | -7.43% | 4.27% | 9.59% | 22.76% | 9.06% | 9.04% | 14.28% | 12.64% | 16.16% | 11.50% | 13.69% | 11.65% |
| EPS | -0.32 | 0.18 | 0.44 | 1.17 | 0.30 | 0.29 | 0.56 | 0.52 | 0.74 | 0.37 | 0.49 | 0.47 |
| EPS Diluted | -0.32 | 0.18 | 0.44 | 1.17 | 0.30 | 0.29 | 0.56 | 0.52 | 0.74 | 0.37 | 0.49 | 0.47 |
| Weighted Avg Shares Out | 168.95M | 171.19M | 171.19M | 168.75M | 156.80M | 155.91M | 130.33M | 117.09M | 117.20M | 117.56M | 110.31M | 110.31M |
| Weighted Avg Shares Out (Dil) | 168.95M | 171.19M | 171.19M | 168.75M | 156.80M | 155.91M | 130.33M | 117.09M | 117.20M | 117.56M | 110.31M | 110.31M |
Source: https://incomestatements.info
Category: Stock Reports